Search results for gaucher disease

Genzyme Corp. (NASDAQ: GENZ) reported today that a preliminary analysis of data from an ongoing open-label Phase 2 clinical trial of its investigational oral therapy Genz-112638 showed that the compo read more »
Discuss   Add this link to...  Bury